Related Experiment Videos
Conventional drug therapy in inflammatory bowel disease
1University of Kansas Medical Center, Kansas City.
Gastroenterology Clinics of North America
|September 1, 1995
Summary
Effective inflammatory bowel disease treatment involves 5-aminosalicylic acid (5-ASA) formulations, glucocorticoids for remission, and potentially immunosuppressants or antibiotics for refractory cases. Combination therapy is often necessary for achieving remission.
Area of Science:
- Gastroenterology
- Internal Medicine
- Pharmacology
Background:
- Inflammatory bowel disease (IBD) management requires tailored therapeutic strategies.
- Current treatments focus on inducing and maintaining remission.
Purpose of the Study:
- To outline current therapeutic approaches for inflammatory bowel disease.
- To emphasize the role of 5-aminosalicylic acid (5-ASA) and adjunct therapies.
Main Methods:
- Review of conventional and emerging treatments for IBD.
- Discussion on drug selection based on disease extent, patient tolerance, and severity.
- Consideration of combination drug regimens.
Main Results:
- 5-ASA derivatives are foundational, with sulfasalazine as initial therapy and newer agents for intolerance or higher doses.
- Glucocorticoids are crucial for remission induction, with prompt tapering advised.
- Immunosuppressants (azathioprine, 6-mercaptopurine) and antibiotics (metronidazole, ciprofloxacin) offer options for refractory disease.
Conclusions:
- Optimal IBD management often necessitates a combination of therapies.
- Drug delivery methods should align with disease extent.
- Further research is needed to define ideal regimens for distinct IBD patient subsets.